Inventiva's Lanifibranor Reaches Primary Endpoint in Phase 2 Study for MASH Drug
Monday, 18 March 2024, 21:45
Inventiva's Lanifibranor Phase 2 Success
Inventiva (IVA) announced that its drug lanifibranor has achieved the primary efficacy endpoint in a Phase 2 study aimed at treating patients with MASH/NASH and type 2 diabetes. This milestone marks a significant advancement in the field of medical research.
Key Highlights:
- Successful Outcome: The study results reveal a positive response to lanifibranor, indicating its potential as a viable treatment option.
- Patient Impact: Patients with MASH/NASH and type 2 diabetes could benefit from this innovative drug.
With this promising development, the healthcare sector anticipates new possibilities for managing these health conditions effectively.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.